Korus™
Application Note
Transforming Monocyte Based Cell Therapy Manufacturing via Elutriation
As manufacturing of cell therapies continues to scale out, manufacturing challenges have presented logistical and commercial difficulties, such as inconsistent starting material due to variable cell population and long processing times that can reduce cell viability and downstream process performance.
In this application note we share data highlighting how the Korus™ platform can reduce these manufacturing inefficiencies and variability with its fully automated, closed, counter flow centrifugation system that supports cell population enrichment, washing and media exchange.
This paper will review how:
- Korus can successfully produce an enriched Monocyte population with high purity, recovery, and viability.
- Starting with fresh apheresis material a single operator can yield an enriched monocyte population from a full leukopak in less than an hour.
Download the Application Note
The Korus system is for research, laboratory, or further manufacturing use only. It is not intended as a medical device in therapeutic or diagnostic procedures. Customers are responsible for validating the use of Korus within their process or therapy. This document is provided without express or implied warranties. Invetech and its affiliates do not guarantee and shall bear no liability arising from or connected to the accuracy, reliability, currency, or completeness of any contents of this document, which may be updated or replaced at any time and without notice. To the maximum extent permitted by applicable law, Invetech and its affiliates shall not be liable for any indirect, special, incidental, consequential or other losses arising out of or in connection with any use or reliance on this document.